2 weeks Ago By ABMN Staff
Legal & General Group Plc grew its position in Fulgent Genetics, Inc. ( NASDAQ:FLGT – Free Report ) by 5.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
The firm owned 98,077 shares of the company’s stock after buying an additional 4,883 shares during the quarter. Legal & General Group Plc owned approximately 0.32% of Fulgent Genetics worth $1,811,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Invesco Ltd. increased its stake in shares of Fulgent Genetics by 14.
0% during the 4th quarter. Invesco Ltd. now owns 181,714 shares of the company’s stock worth $3,356,000 after purchasing an additional 22,301 shares during the last quarter.
Federated Hermes Inc. lifted its position in shares of Fulgent Genetics by 4.4% during the 4th quarter.
Federated Hermes Inc. now owns 41,882 shares of the company’s stock worth $774,000 after purchasing an additional 1,774 shares during the last quarter. Russell Investments Group Ltd.
boosted its stake in Fulgent Genetics by 267.4% during the 4th quarter. Russell Investments Group Ltd.
now owns 2,693 shares of the company’s stock valued at $50,000 after purchasing an additional 1,960 shares during the period. Dynamic Technology Lab Private Ltd grew its holdings in Fulgent Genetics by 15.2% in the 4th quarter.
Dynamic Technology Lab Private Ltd now owns 15,129 shares of the company’s stock valued at $280,000 after buying an additional 1,995 shares during the last quarter. Finally, ExodusPoint Capital Management LP increased its position in Fulgent Genetics by 75.3% in the 4th quarter.
ExodusPoint Capital Management LP now owns 92,197 shares of the company’s stock worth $1,703,000 after buying an additional 39,618 shares during the period. 48.06% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In Several equities research analysts have recently issued reports on FLGT shares. Piper Sandler lowered their price objective on shares of Fulgent Genetics from $22.00 to $16.
00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. StockNews.com upgraded shares of Fulgent Genetics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 5th.
Insider Transactions at Fulgent Genetics In related news, CFO Paul Kim purchased 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were acquired at an average price of $15.96 per share, with a total value of $1,596,000.
00. Following the purchase, the chief financial officer now directly owns 348,282 shares in the company, valued at $5,558,580.72.
This represents a 40.28 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website .
31.76% of the stock is owned by insiders. Fulgent Genetics Trading Down 0.
8 % FLGT opened at $18.88 on Friday. The stock’s 50 day simple moving average is $17.
30 and its 200-day simple moving average is $18.15. The stock has a market cap of $582.
75 million, a PE ratio of -3.42 and a beta of 1.36.
Fulgent Genetics, Inc. has a 1 year low of $14.57 and a 1 year high of $25.
11. About Fulgent Genetics ( Free Report ) Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Further Reading Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter ..
